Company Overview - IDEXX Laboratories, Inc. is a leader in veterinary diagnostics, software, and water testing solutions, based in Westbrook, Maine, with a market cap of $45.7 billion [1] - The company develops diagnostic instruments, test kits, software, and laboratory services for veterinarians, farmers, and laboratories to monitor animal health and detect diseases [1] Market Position - IDEXX is classified as a "large-cap stock" and is recognized as a market leader in veterinary diagnostics, benefiting from strong brand recognition and a large installed base of diagnostic instruments [2] - The company's solutions are utilized in over 175 countries, indicating a robust global presence [2] Stock Performance - Shares of IDEXX have decreased by 25.5% from their 52-week high of $769.98 and have dipped 18.5% over the past three months, underperforming the S&P 500 Index's decline of 2.9% [3] - Over the past six months, IDEXX shares are down 10.5%, while the S&P 500 has shown marginal returns [5] - Despite recent declines, IDEXX stock has increased by 41.2% over the past 52 weeks, outperforming the S&P 500's 20.1% increase during the same period [5] Recent Financial Performance - On February 2, IDEXX reported a strong fourth-quarter 2025 performance with revenue of $1.1 billion and adjusted earnings of $3.08 per share, both exceeding analyst expectations [6] - However, the gross margin of 60.3% fell short of the consensus forecast of 61% [6] Competitive Landscape - IDEXX has outperformed its main competitor, Zoetis Inc., which has seen a decline of 27.8% over the past 52 weeks and 22% over the past six months [7] - Analysts maintain a cautiously optimistic outlook for IDEXX, with a consensus rating of "Moderate Buy" and a mean price target of $773.58, representing a 34.8% premium to current levels [7]